Kaiming Zhang

Dr. Kaiming Zhang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Cell Proliferation
Verified
Journal Article
Open access
LPLiqin Ping
Liqin Ping
LZLewei Zhu
Lewei Zhu
NCNian Chen
Nian Chen
XLXikun Liu
Xikun Liu
JZJirui Zhong
Jirui Zhong
KZKaiming Zhang
Kaiming Zhang
Endocrine resistance is a leading cause of mortality in oestrogen receptor‐positive and human epidermal growth factor receptor 2‐negative (ER+HER2−) breast cancer (BC), highlighting the urgent need to understand its underlying molecular mechanisms and identify potentially resistant patients for effective management. In this study, we constructed endocrine‐resistant cell lines through long‐term oestrogen deprivation and identified differentially expressed genes (DEGs) via transcriptome analysis. Key endocrine‐resistant genes were defined through Cox regression analysis. Our findings revealed that the genes CLEC3A, PCDH10, and ST3GAL1 were significantly upregulated in endocrine‐resistant cells and serve as independent prognostic factors for ER+HER2− BC patients. We developed an endocrine resistance score (ERS), and a nomogram model incorporating ERS demonstrated robust predictive capabilities for patient prognosis. Single‐cell RNA sequencing analysis demonstrated that the ERS and the three core genes constituting the ERS were significantly upregulated in tissue specimens from patients with resistance to endocrine neoadjuvant therapy. Additionally, knocking down CLEC3A, PCDH10, and ST3GAL1 led to reduced malignancy progression in endocrine‐resistant BC cells. Mechanistic studies revealed that CLEC3A promotes endocrine resistance by upregulating the PI3K‐AKT pathway. This study suggests that CLEC3A, PCDH10, and ST3GAL1 are associated with endocrine resistance and can reflect the prognosis of ER+HER2− BC patients receiving endocrine therapy, providing potential therapeutic targets and a valuable prognostic indicator for clinicians.

19 May 2025 in Cancer Research
Verified
Journal Article
Closed access
JSJia-Lu Shan
Jia-Lu Shan
KZKaiming Zhang
Kaiming Zhang
WZWen-Qing Zhong
Wen-Qing Zhong
XYXiao-Yu Yang
Xiao-Yu Yang
ZLZhi-Ling Li
Zhi-Ling Li
RDRong Deng
Rong Deng
NRAS is commonly mutated in several different types of human cancer. NRAS-mutant tumors are aggressive and associated with poor outcomes. Although the development of targeted therapies as well as immune checkpoint inhibitors has led to a substantial improvement in the overall survival of patients with NRAS wild-type (WT) tumors, current therapies for NRAS-mutant cancers are limited. In this study, analysis of RNA sequencing data revealed a downregulation of the type I IFN response in NRAS-mutant tumors compared with NRAS WT tumors, which was associated with poor prognosis in NRAS-mutant melanoma. Knockdown of mutant NRAS, but not WT NRAS, enhanced the activation of cyclic GMP-AMP synthase (cGAS)–STING signaling. The formation of a trimeric complex between TBK1, STING, and IFN regulatory factor 3, which is required for the activation and nuclear translocation, was blocked in NRAS-mutant tumor cells. Inactivation of innate immune signaling by mutant NRAS altered cytokine production, resulting in cell autonomous and non–cell autonomous signaling to prevent tumor cell death and in evasion of tumor-immune surveillance. Screening of drugs for the ability to stimulate the release of CXCL10 revealed that SOS1 inhibitors reactivated cGAS–STING signaling in NRAS-mutant tumor cells. Importantly, combining SOS1 inhibitors with STING agonists maximized the activation of cGAS–STING signaling and elicited an increased antitumor immune response in vitro and in vivo. Overall, this study provides insights into the regulation of antitumor immunity by mutant NRAS and uncovers a potential strategy for treating NRAS-mutant cancer. Significance: Suppression of innate immune signaling in NRAS-mutant tumors results from downregulation of the cGAS–STING axis and can be reversed using SOS1 inhibitors combined with STING agonists to restrain NRAS-mutant tumor growth.

20 June 2024 in Clinical and Translational Medicine
Verified
Journal Article
Open access
QCQingshan Chen
Qingshan Chen
FGFenglin Gao
Fenglin Gao
JWJunwan Wu
Junwan Wu
KZKaiming Zhang
Kaiming Zhang
TDTian Du
Tian Du
JTJun Tang
Jun Tang
Background: Mitochondrial outer membrane permeabilisation (MOMP) plays a pivotal role in cellular death and immune activation. A deeper understanding of the impact of tumour MOMP on immunity will aid in guiding more effective immunotherapeutic strategies.Methods: A comprehensive pan‐cancer dataset comprising 30 cancer‐type transcriptomic cohorts, 20 immunotherapy transcriptomic cohorts and three immunotherapy scRNA‐seq datasets was collected and analysed to determine the influence of tumour MOMP activity on clinical prognosis, immune infiltration and immunotherapy effectiveness. Leveraging 65 scRNA‐Seq datasets, the MOMP signature (MOMP.Sig) was developed to accurately reflect tumour MOMP activity. The clinical predictive value of MOMP.Sig was explored through machine learning models. Integration of the MOMP.Sig model and a pan‐cancer immunotherapy CRISPR screen further investigated potential targets to overcome immunotherapy resistance, which subsequently underwent clinical validation.Results: Our research revealed that elevated MOMP activity reduces mortality risk in cancer patients, drives the formation of an anti‐tumour immune environment and enhances the response to immunotherapy. This finding emphasises the potential clinical application value of MOMP activity in immunotherapy. MOMP.Sig, offering a more precise indicator of tumour cell MOMP activity, demonstrated outstanding predictive efficacy in machine‐learning models. Moreover, with the assistance of the MOMP.Sig model, FOXO1 was identified as a core modulator that promotes immune resistance. Finally, these findings were successfully validated in clinical immunotherapy cohorts of skin cutaneous melanoma and triple‐negative breast cancer patients.Conclusions: This study enhances our understanding of MOMP activity in immune modulation, providing valuable insights for more effective immunotherapeutic strategies across diverse tumours.

Verified
Journal Article
Open access
PDF file
KZKaiming Zhang
Kaiming Zhang
PLping liqin
ping liqin
XOXueqi Ou
Xueqi Ou
MBMeiheban Bazhabayi
Meiheban Bazhabayi
XXXiangsheng Xiao
Xiangsheng Xiao
Background: Systemic inflammatory response is related to the occurrence, progression, and prognosis of cancers. In this research, a novel systemic inflammation response score (SIRS) was calculated, and its prognostic value for postoperative stage I-III breast cancer (BC) patients was analyzed. Methods: 1583 BC patients were included in this research. Patients were randomly divided into a training cohort (n = 1187) and validation cohort (n = 396). SIRS was established in the training cohort based on independent prognostic hematological indicator, its relationship between prognosis and clinical features was analyzed. Then, a nomogram consisted of SIRS and clinical features was established, its performance was examined by calibration plots and receiver operating characteristic curve analysis. Results: The SIRS was an independent prognostic indicator for BC patients, and a high-SIRS was related to multifocality, advanced N stage, and worse prognosis. Incorporating SIRS into a nomogram could accurately predict the prognosis of BC patients, the results of receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) of nomogram was up to 0.806 in training cohort and 0.905 in the validation cohort. Conclusion: SIRS was associated with the prognosis of patients with breast cancer. Nomogram based on SIRS can accurately predict the prognosis of breast cancer patients.

15 August 2025
Verified
Other
Open access
JSJia-Lu Shan
Jia-Lu Shan
KZKaiming Zhang
Kaiming Zhang
WZWen-Qing Zhong
Wen-Qing Zhong
XYXiao-Yu Yang
Xiao-Yu Yang
ZLZhi-Ling Li
Zhi-Ling Li
RDRong Deng
Rong Deng
NRAS is commonly mutated in several different types of human cancer. NRAS-mutant tumors are aggressive and associated with poor outcomes. Although the development of targeted therapies as well as immune checkpoint inhibitors has led to a substantial improvement in the overall survival of patients with NRAS wild-type (WT) tumors, current therapies for NRAS-mutant cancers are limited. In this study, analysis of RNA sequencing data revealed a downregulation of the type I IFN response in NRAS-mutant tumors compared with NRAS WT tumors, which was associated with poor prognosis in NRAS-mutant melanoma. Knockdown of mutant NRAS, but not WT NRAS, enhanced the activation of cyclic GMP-AMP synthase (cGAS)–STING signaling. The formation of a trimeric complex between TBK1, STING, and IFN regulatory factor 3, which is required for the activation and nuclear translocation, was blocked in NRAS-mutant tumor cells. Inactivation of innate immune signaling by mutant NRAS altered cytokine production, resulting in cell autonomous and non–cell autonomous signaling to prevent tumor cell death and in evasion of tumor-immune surveillance. Screening of drugs for the ability to stimulate the release of CXCL10 revealed that SOS1 inhibitors reactivated cGAS–STING signaling in NRAS-mutant tumor cells. Importantly, combining SOS1 inhibitors with STING agonists maximized the activation of cGAS–STING signaling and elicited an increased antitumor immune response in vitro and in vivo. Overall, this study provides insights into the regulation of antitumor immunity by mutant NRAS and uncovers a potential strategy for treating NRAS-mutant cancer.Significance:Suppression of innate immune signaling in NRAS-mutant tumors results from downregulation of the cGAS–STING axis and can be reversed using SOS1 inhibitors combined with STING agonists to restrain NRAS-mutant tumor growth.

15 August 2025
Verified
Other
Open access
JSJia-Lu Shan
Jia-Lu Shan
KZKaiming Zhang
Kaiming Zhang
WZWen-Qing Zhong
Wen-Qing Zhong
XYXiao-Yu Yang
Xiao-Yu Yang
ZLZhi-Ling Li
Zhi-Ling Li
RDRong Deng
Rong Deng
Supplementary Fig. S3. The suppression of cGAS-STING pathway in NRAS mutant cells mediates immune escape. A. Flow cytometry measuring the DCs mature markers (MHC II and CD86), when co-cultured with the indicated tumor cells pre-treated with poly(dA:dT). B. Immunoblot in NCI-H1299 cells expressing sgRNA targeting STING. C. Flow cytometry measuring the DCs mature markers (MHC II and CD86), when co-cultured with the indicated tumor cells pre-treated with HT-DNA. D-E. Flow cytometry measuring the cytotoxicity of PBMCs that killing the cancer cells pre-treated with poly(dA:dT) (D) and HT-DNA(E). F. FACS analysis of CD8+T, NK1.1+, and IFNγ+ or Granzyme B+ in CD8+ T cell populations and NK cell populations from the isolated TILs. Representative dot plots from a representative mouse for each group.